Trazocalm® – Keep your shelf compliant with APVMA-approved* Trazodone
Trazodone is frequently used in veterinary practice to support dogs in situations where stress, anxiety or activity restriction can present a challenge — from urgent use situations in clinic through to longer-term post-operative confinement following orthopaedic surgery.
NSW Health advises that compounded medicines should only be used when an approved product is unavailable or unsuitable, and practitioners must comply with relevant laws and professional codes.¹ The responsibility for that choice remains with the prescribing veterinarian.2 Where a regulated option such as Trazocalm® exists, choosing it supports both patient safety and professional accountability.
The AVA policy states using suitable registered veterinary medicines, or products administered under an APVMA permit, where available, in preference to compounded pharmaceuticals.2
Why choose Trazocalm® for your clinic shelf?
With APVMA approval*, Australian clinical evidence, a tested formulation, flexible dosing and a 3-year shelf life, Trazocalm® is designed for practical clinic stocking. Keeping it on hand gives veterinary teams ready access to a consistent, purpose-designed trazodone product when needed — whether supporting an urgent-use situation in clinic or planned post-operative . Its availability through veterinary wholesalers also makes it simple to maintain reliable stock without relying on last-minute sourcing when time matters.
Proven evidence in Australian studies and Australian dogs
Recent Australian studies using the Trazocalm® formulation in dogs demonstrated improved handling, compliance and positioning, with reduced reactivity from doses as low as 5 mg/kg and a favourable safety profile.3 The formulation also demonstrated rapid dissolution, with the majority of active release occurring within the first 15 minutes.3
For post-operative confinement following orthopaedic procedures, Trazocalm® is indicated at a starting dose of 3.5 mg/kg, with dosing up to 7–10 mg/kg for a minimum of four weeks. Treatment may be extended following veterinary reassessment.4 Trazodone has also been shown to support confinement tolerance and calmness during post-operative recovery.4
For situational anxiety associated with transport and veterinary care, Trazocalm® is administered approximately 90 minutes prior, with a starting dose of 3.5 mg/kg and dosing up to 9–12 mg/kg.5 Effects may begin within 30–45 minutes, supporting calmer handling during veterinary visits.5
Keep Trazocalm® on hand when your patients need it. Simply order Trazocalm® through your preferred veterinary wholesaler, including Lyppard, ZebraVet, Cenversa, Provet and Ellar.

Learn more about Trazocalm® and the Australian studies completed in Australian dogs. Download here.
References
*Trazocalm® is a veterinary medicine approved under APVMA permit PER93844. This permit authorises supply of an unregistered . An application has been made to register the product.
1NSW Health. Compounded medicines for animal use. Current as at 23 October 2026. Available at: https://www.health.nsw.gov.au/pharmaceutical/Pages/compound-animal-medicines.aspx
2Australian Veterinary Association. Veterinary use of compounded pharmaceuticals policy. Available at: AVA policy on compounded pharmaceuticals.
3InVetro. Data on file. Australian efficacy, safety and dissolution studies for Trazocalm®.
4Gruen M et al. Use of trazodone to facilitate postsurgical confinement in dogs. Journal of the American Veterinary Medical Association. 2014;245(3):296–301.
5Kim Y et al. Effects of trazodone on behavioral and physiological signs of stress in dogs during veterinary visits. Journal of the American Veterinary Medical Association. 2022;260(8):876–883.
